Jacqueline E. Shea - May 10, 2024 Form 4 Insider Report for INOVIO PHARMACEUTICALS, INC. (INO)

Role
Chief Executive Officer, Director
Signature
/s/ Jacqueline E. Shea
Stock symbol
INO
Transactions as of
May 10, 2024
Transactions value $
-$25,475
Form type
4
Date filed
5/13/2024, 04:57 PM
Previous filing
Feb 28, 2024
Next filing
May 16, 2024

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction INO Common Stock Options Exercise +5.5K +26.81% 26K May 10, 2024 Direct F1, F2
transaction INO Common Stock Tax liability -$25.5K -2.39K -9.2% $10.65 23.6K May 10, 2024 Direct F3

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction INO Restricted Stock Unit Options Exercise $0 -5.5K -50% $0.00 5.5K May 10, 2024 Common Stock 5.5K Direct F1, F2
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Each restricted stock unit represents a contingent right to receive one share of common stock. The vesting schedule for the 16,500 restricted stock units is as follows: 5,500 shares vested on May 10, 2023; 5,500 shares vested on May 10, 2024; and 5,500 shares will vest on May 10, 2025. Vested restricted stock units can be settled in shares of common stock, cash or a combination of both.
F2 Gives effect to a 1-for-12 reverse stock split effected by the Issuer on January 24, 2024.
F3 The transaction reported represents the withholding of shares by the issuer to satisfy the reporting person's tax withholding obligations in connection with the vesting and settlement of the restricted stock unit award reported in the immediately preceding row and described in footnote (1) herein.